CoChat

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

Open access
Kellerer, Monika, Kaltoft, Margit Staum, Lawson, Jack, Nielsen, Lasse Lykke, Strojek, Krzysztof, Tabak, Ömür, Jacob, Stephan · 2022 · Diabetes, Obesity and Metabolism
Cited by 86

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Aim: To compare the efficacy and safety of once‐weekly (OW) semaglutide versus thrice‐daily (TID) insulin aspart (IAsp) in participants with inadequately controlled type 2 diabetes (T2D) treated with insulin glargine (IGlar) and metformin. Materials and Methods: SUSTAIN 11 (NCT03689374) was a randomized (1:1), parallel, open‐label, multinational, phase 3b trial. After a 12‐week run‐in to optimize once‐daily IGlar U100, 1748 adults with T2D (HbA1c >7.5% to ≤10.0%) were randomized to OW semaglutide or TID IAsp as add‐on to optimized IGlar and metformin for 52 weeks. The primary outcome was change in HbA1c from randomization to week 52. Confirmatory secondary endpoints included the occurrence of severe hypoglycaemic episodes and change in body weight (BW). Safety was assessed. Results: HbA1c (randomization: 8.6% [70.0 mmol/mol]) decreased by 1.5% points (16.6 mmol/mol) and 1.2% points (13.4 mmol/mol) with semaglutide (n = 874) and IAsp (n = 874), respectively (estimated treatment difference [ETD] −0.29% points [95% confidence interval {CI} −0.38; −0.20]; P < .0001 for non‐inferiority). Few severe hypoglycaemic episodes were recorded in either group, with no statistically significant difference between the groups. Change in BW from randomization (87.9 kg) to week 52 was in favour of semaglutide (−4.1 kg) versus IAsp (+2.8 kg) (ETD −6.99 kg [95% CI −7.41; −6.57]). A higher proportion of participants experienced adverse events with semaglutide (58.5%) versus IAsp (52.1%); most were mild to moderate. Conclusions: In this basal insulin‐treated population, OW semaglutide improved glycaemic control to a greater extent than TID IAsp and provided numerically greater weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14765

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 86

Metadata

Authors
Kellerer, M., Kaltoft, M. S., Lawson, J., Nielsen, L. L., Strojek, K., Tabak, Ö., & Jacob, S.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2022-06-29
Volume
24
Issue
9
Pages
1788-1799
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W4280597148
Cited by
86
References
22
FWCI
8.58
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial. https://app.cochat.ai/papers/10.1111/dom.14765
The paper
Kellerer, M., Kaltoft, M. S., Lawson, J., Nielsen, L. L., Strojek, K., Tabak, Ö., & Jacob, S. (2022). Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14765

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.